Stocks · News reference
Cerenome, Inc. reported new preclinical data demonstrating the immunomodulatory properties of its lead radiotherapeutic candidate, REYOBIQ™, in ovarian cancer models.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cerenome, Inc. announced that interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ™ will be presented at the Society for Neuro-Oncology (SNO) 31st Annual Meeting.
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging
Filed: 2026-10-02 AccNo: 0001193125-26-411259 Size: 13 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits